KPV
Preclinical — cells or animals
Research-only / investigational — not FDA approved
Investigational; no FDA-approved drug label is established for this entry. Source: FDA: safety concerns for nominated peptide substances
What it is
A peptide studied in intestinal and immune cells and mouse models. Source: Cell and mouse study: KPV and intestinal inflammation
What it has been studied for
Intestinal inflammation in preclinical models. Source: Cell and mouse study: KPV and intestinal inflammation
Mechanism
Cell uptake through the PepT1 transporter was associated with reduced inflammatory signaling. Source: Cell and mouse study: KPV and intestinal inflammation
Documented dosing
No applicable general-use human dose range, frequency or cycle is documented here. Numbers from other routes, formulations or conditions are not interchangeable.
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
FDA identifies unresolved safety concerns for this substance. Source: FDA: safety concerns for nominated peptide substances
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- Cell and mouse study: KPV and intestinal inflammation · Research publication
- FDA: safety concerns for nominated peptide substances · Clinical / regulatory reference
